Your Search for 'sanofi-aventis - Pipeline - Products - Performance - Potential' returned 82 results - Page 1 of 5

• Sanofi-Aventis (SAN) - Financial and Strategic SWOT Analysis Review

  EURO€ 96.00USD$ 125.00GBP£ 81.00AUD$ 122.00JPY¥ 12,342.00SEK 821,00CHF 118.00CAD$ 127.00 GlobalData, Apr 2011 , Pages: 57
  Sanofi-Aventis - Key Operational Employees Sanofi-Aventis - Major Products and Services Sanofi-Aventis - Pharmaceutical Pipeline Products Data Sanofi-Aventis, Pipeline Products by Therapy Area ...

• Sanofi- Aventis Market Share Analysis

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Nov 2009 , Pages: 31
  Overview 4.6 Major Products and Services 4.6.1 Overview 5 History 6 SWOT Analysis 6.1 Overview 6.2 Sanofi-Aventis Strengths 6.2.1 Broad Product Portfolio 6.2.2 Consistent Revenue Growth 6.2.3 Strong ...

• Sanofi (SAN) - Financial and Strategic SWOT Analysis Review

  EURO€ 96.00USD$ 125.00GBP£ 81.00AUD$ 122.00JPY¥ 12,342.00SEK 821,00CHF 118.00CAD$ 127.00 GlobalData, Mar 2013 , Pages: 84
  adolescent booster, meningitis and travel, endemic and measles, mumps and rubella (MMR). Sanofi Key Recent Developments Mar 08, 2013: Zealand Pharma Provides Update On Pipeline Products Feb 19, 2013: Sanofi ...

• Genzyme Corporation

  EURO€ 4,381.00USD$ 5,700.00GBP£ 3,686.00AUD$ 5,575.00JPY¥ 562,778.00SEK 37 425,00CHF 5'372.00CAD$ 5,808.00 Datamonitor, May 2011 , Pages: 95
  sales performance - Understand the level of sales growth and portfolio diversification Genzyme will offer Sanofi-Aventis, post acquisition Executive Summary Key findings Genzyme prescription ...

• Meningitis - Pipeline Analysis and Market Forecasts to 2016

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Mar 2010 , Pages: 39
  GlaxoSmithKline - Meningitis Pipeline 6.4 Sanofi-aventis 6.4.1 Company Overview 6.4.2 Business Description 6.4.3 Sanofi-aventis Infectious Diseases Pipeline 6.4.4 Sanofi-aventis - Meningitis Pipeline 6.5 ...

• Lung Cancer Therapeutics Market Outlook and Pipeline Analysis

  EURO€ 1,918.00USD$ 2,495.00GBP£ 1,613.00AUD$ 2,440.00JPY¥ 246,339.00SEK 16 382,00CHF 2'352.00CAD$ 2,542.00 Arrowhead Publishers, Nov 2009
  maximize your product’s commercial potential - Gain an impartial perspective of the strategies used between competing companies involved in the lung cancer pipeline to enhance your product’s performance 1 ...

• Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies

  EURO€ 2,242.00USD$ 2,534.00GBP£ 1,495.00AUD$ 3,504.00JPY¥ 303,862.00SEK 19 933,00CHF 3'337.00CAD$ 3,250.00 Spectra Intelligence, Nov 2011 , Pages: 66
  interest for major pharmaceutical companies, reflecting the view that orphan drugs were specialty products with limited market potential thus offering a poor fit for companies based upon the blockbuster ...

• Global Biopharma Outlook 2011: Major US and EU

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 MP Advisors, Feb 2011 , Pages: 90
  ? Avastin or Lucentis - Major Pipeline molecules with expected Filing Sanofi Aventis: Will take longer to deliver - R & D pipeline- Strong competition provide limited potential - Terflunomide in ...

• Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Jun 2011 , Pages: 89
  Deals, 2009-2011 Table 44: Sanofi-Aventis – Promising Molecules in Pipeline for Oncology, 2011 Table 45: Sanofi-Aventis Key Deals, 2010-2011 Table 46: Synta Pharmaceuticals – Promising Molecules in ...

• The CNS Market Outlook to 2010

  EURO€ 2,210.00USD$ 2,875.00GBP£ 1,859.00AUD$ 2,812.00JPY¥ 283,857.00SEK 18 877,00CHF 2'710.00CAD$ 2,930.00 Scripp Business Insights, Oct 2005
  forecasts GSK Marketed products R&D compounds CNS portfolio sales forecasts Lilly Marketed products R&D compounds CNS portfolio sales forecasts Sanofi-Aventis Marketed products R&D compounds ...

• The Cancer Market Outlook to 2010

  EURO€ 2,210.00USD$ 2,875.00GBP£ 1,859.00AUD$ 2,812.00JPY¥ 283,857.00SEK 18 877,00CHF 2'710.00CAD$ 2,930.00 Scripp Business Insights, Nov 2005
  R&D compounds Cancer portfolio sales forecasts Sanofi-Aventis Marketed products R&D compounds Cancer portfolio sales forecasts Amgen Marketed products R&D compounds Cancer portfolio sales ...

• Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market

  EURO€ 2,690.00USD$ 3,500.00GBP£ 2,263.00AUD$ 3,423.00JPY¥ 345,565.00SEK 22 980,00CHF 3'299.00CAD$ 3,566.00 GBI Research, Feb 2011 , Pages: 195
  Product Portfolio 181 11.3.4 SWOT Profile 182 11.4 Bayer HealthCare AG 182 11.4.1 Overview 183 11.4.2 Financial Performance 183 11.4.3 Product Portfolio 183 11.4.4 SWOT Profile 183 11.5 Sanofi-Aventis 184 ...

• Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Dec 2008 , Pages: 267
  Sales performance 193 Geographic spread 194 Seasonality 195 Role of vaccines in overall company portfolio 196 Portfolio analysis 198 Prevnar 199 Pipeline analysis 201 Prevnar 13 203 ACC-001 204 MnB ...

• Pipeline and Commercial Insight: Insomnia - Future of Innovative Orexin Drug Class in Doubt

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Jul 2010 , Pages: 257
  Pipeline and Commercial Insight: Insomnia - Future of Innovative Orexin Drug Class in Doubt The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards ...

• Innovative and Targeted Cancer Therapies: Key Technologies, New Applications and Leading Players

  EURO€ 2,210.00USD$ 2,875.00GBP£ 1,859.00AUD$ 2,812.00JPY¥ 283,857.00SEK 18 877,00CHF 2'710.00CAD$ 2,930.00 Scripp Business Insights, Jul 2007 , Pages: 128
  Leading oncology strategies 91 Lifecycle management growth 92 Genentech 92 Roche 95 Diversification growth 98 Novartis 98 Pfizer 101 Bristol-Myers Squibb 103 Franchise development growth 105 Sanofi-Aventis ...

• Stakeholder Opinions: Targeting Nerve Growth Factor for Pain Therapy - Groundbreaking class to breathe new life into saturated market

  EURO€ 2,921.00USD$ 3,800.00GBP£ 2,457.00AUD$ 3,717.00JPY¥ 375,185.00SEK 24 950,00CHF 3'582.00CAD$ 3,872.00 Datamonitor, Mar 2010 , Pages: 85
  product profile versus current comparator therapy, 2010 Table 8: Nerve growth factor (NGF) modulators pipeline, 2009 Table 9: Tanezumab (RN624, Sanofi-Aventis/Regeneron) - drug profile, 2010 Table 10 ...

• The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact

  EURO€ 2,114.00USD$ 2,750.00GBP£ 1,778.00AUD$ 2,690.00JPY¥ 271,516.00SEK 18 056,00CHF 2'592.00CAD$ 2,802.00 Arrowhead Publishers, Jan 2011
  forecasts to 2020 to maximize your products commercial potential - Assess opportunities and risks influencing R&D in therapeutic cancer vaccines - Gain an impartial perspective of strategies that can be ...

• The Top Five Global Pharma Companies; Where they are Now and Where they heading?

  EURO€ 999.00USD$ 1,300.00GBP£ 840.00AUD$ 1,271.00JPY¥ 128,320.00SEK 8 533,00CHF 1'225.00CAD$ 1,324.00 i3 Consult, Dec 2008 , Pages: 25
  many as 4-6 new filings per year 2008-2011. Sanofi-Aventis’ strong 2008 second quarter performance qualifies the company as a star company however this status is likely to come under threat; key ...

• PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013

  EURO€ 455.00USD$ 425.00GBP£ 258.00AUD$ 619.00JPY¥ 52,150.00SEK 3 667,00CHF 610.00CAD$ 568.00 Cambridge Healthtech Institute, Jun 2012
  Healthcare Pharmaceuticals Johnson & Johnson Sanofi-aventis Lifestyle Drugs Market Continues to Grow Development Pipelines of Selected Leading Drug Companies: Number of Products by Stage of Development ...

• The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights

  EURO€ 1,345.00USD$ 1,750.00GBP£ 1,132.00AUD$ 1,712.00JPY¥ 172,783.00SEK 11 490,00CHF 1'649.00CAD$ 1,783.00 Arrowhead Publishers, Oct 2010 , Pages: 385
  product's performance in the pain therapeutics market - Identify key pain therapeutic products in late-phase development - Benchmark the competition via sales forecasts to 2015 1 Executive Summary 1.1 ...